- Previous Close
0.00 - Open
39.53 - Bid 28.12 x 43500
- Ask 28.65 x 40000
- Day's Range
39.53 - 39.53 - 52 Week Range
26.38 - 52.38 - Volume
100 - Avg. Volume
127 - Market Cap (intraday)
911.533M - Beta (5Y Monthly) 2.08
- PE Ratio (TTM)
53.59 - EPS (TTM)
0.54 - Earnings Date Apr 22, 2025 - Apr 28, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden, the United States, the Netherlands, Italy, North and South America, Europe, the Middle East, Africa, the Asia Pacific, and Oceania. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. The company was incorporated in 1998 and is headquartered in Mölndal, Sweden.
www.xvivogroup.comRecent News: XVIPF
View MorePerformance Overview: XVIPF
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XVIPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XVIPF
View MoreValuation Measures
Market Cap
890.20M
Enterprise Value
852.10M
Trailing P/E
53.43
Forward P/E
53.48
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.19
Price/Book (mrq)
4.25
Enterprise Value/Revenue
10.38
Enterprise Value/EBITDA
96.58
Financial Highlights
Profitability and Income Statement
Profit Margin
20.94%
Return on Assets (ttm)
2.40%
Return on Equity (ttm)
8.40%
Revenue (ttm)
822.41M
Net Income Avi to Common (ttm)
172.18M
Diluted EPS (ttm)
0.54
Balance Sheet and Cash Flow
Total Cash (mrq)
415.52M
Total Debt/Equity (mrq)
1.58%
Levered Free Cash Flow (ttm)
-125.03M